Fmr LLC Buys 50,419 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Fmr LLC grew its stake in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 3.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,740,900 shares of the biotechnology company’s stock after buying an additional 50,419 shares during the quarter. Fmr LLC owned 0.68% of Adaptimmune Therapeutics worth $1,655,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ADAP. Vontobel Holding Ltd. grew its stake in shares of Adaptimmune Therapeutics by 230.8% in the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 30,000 shares during the last quarter. Fullcircle Wealth LLC purchased a new stake in Adaptimmune Therapeutics in the third quarter worth about $33,000. GSA Capital Partners LLP purchased a new stake in Adaptimmune Therapeutics in the third quarter worth about $95,000. Renaissance Technologies LLC lifted its holdings in Adaptimmune Therapeutics by 28.3% in the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after buying an additional 394,566 shares during the period. Finally, Baillie Gifford & Co. lifted its holdings in Adaptimmune Therapeutics by 10.7% in the third quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock worth $15,944,000 after buying an additional 1,626,657 shares during the period. 31.37% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on ADAP shares. StockNews.com lowered shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Mizuho lowered their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a report on Wednesday, November 27th. Guggenheim reduced their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, HC Wainwright reduced their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $2.79.

Adaptimmune Therapeutics Stock Down 8.1 %

Shares of NASDAQ ADAP opened at $0.58 on Monday. The stock has a market capitalization of $148.44 million, a price-to-earnings ratio of -2.64 and a beta of 2.18. Adaptimmune Therapeutics plc has a 12-month low of $0.43 and a 12-month high of $2.05. The firm’s 50-day moving average price is $0.75 and its 200-day moving average price is $0.97. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.